The following is a summary of the information covered during the Emgality Q&A LIVE on September 24, 2021. Emgality Safety FDA Adverse Events Reporting System Reports on a particular drug or biologic do not mean that the drug or biologic caused the adverse event. FAERS data by themselves are notRead More →
Very little is known about the effect of any COVID-19 vaccine on cluster headache. What little research we have has been done on migraine and tension-type headache. We don’t have answers to all the questions. That doesn’t mean we don’t know anything.Read More →
The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated.Read More →
This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials.Read More →
Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a rare but severely disabling variant within the spectrum of trigeminal autonomic cephalalgia lacking evidence-based treatment.Read More →
CGRP has an important pathophysiological role in cluster headache. Chronic cluster headache patients with insufficient response to other preventive treatments have been receiving individual off-label treatment attempts with CGRP antibodies.Read More →
Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology.Read More →